Interleukin‑1 receptor‑associated kinase 4 as a potential biomarker: Overexpression predicts poor prognosis in patients with glioma-Reference-Cited by-同舟云学术

Interleukin‑1 receptor‑associated kinase 4 as a potential biomarker: Overexpression predicts poor prognosis in patients with glioma

Published:2021-02-03 Issue:4 Volume:21 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Wang Jialin¹,Liu Binfeng¹,Yao Jiawei²,Liu Zhendong³,Wang Hongbo⁴,Zhang Bo⁴,Lian Xiaoyu¹,Ren Zhishuai¹,Liu Liyun³,Gao Yanzheng³

Affiliation:

1. Department of Orthopaedics, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan 450001, P.R. China

2. Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University and Institute of Brain Science, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China

3. Department of Orthopaedics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan 450001, P.R. China

4. Department of Orthopaedics, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan 450001, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients;Advanced Biomedical Research;2024-02

2. The clinical and prognostic significance of CMTM6/PD-L1 in oncology;Clinical and Translational Oncology;2022-03-12

3. Up-regulation of MTHFD2 is associated with clinicopathological characteristics and poor survival in ovarian cancer, possibly by regulating MOB1A signaling;Journal of Ovarian Research;2022-02-08

4. The current state of glioma data registries;Neuro-Oncology Advances;2022-01-01

5. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies;Current Opinion in Hematology;2021-11-05